Welcome to our dedicated page for Pharvaris N.V. news (Ticker: PHVS), a resource for investors and traders seeking the latest updates and insights on Pharvaris N.V. stock.
Pharvaris N.V. (PHVS) news centers on its progress as a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for bradykinin-mediated angioedema. Company updates frequently highlight clinical milestones for its lead candidate deucrictibant, including pivotal Phase 3 programs in hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH).
Investors following PHVS news can expect detailed announcements on clinical trial results and timelines. Recent releases describe RAPIDe-3, a pivotal global Phase 3 study of deucrictibant immediate-release capsule for on-demand treatment of HAE attacks, which met its primary endpoint and all secondary efficacy endpoints with statistical significance and was reported as well tolerated. Other updates cover CHAPTER-3 and CHAPTER-4, Phase 3 studies of the extended-release tablet for long-term prophylaxis of HAE attacks, and CHAPTER-1 Phase 2 data showing sustained reductions in attack rates over long-term treatment.
Pharvaris news also includes information on the CREAATE Phase 3 study in AAE-C1INH, presentations of deucrictibant data at major medical congresses, and summaries of biomarker work such as the kinin assay being clinically validated to characterize bradykinin-mediated angioedema. Financial and corporate updates, including quarterly results, cash runway commentary, and details of public offerings of ordinary shares and pre-funded warrants, are furnished through press releases and Form 6-K filings.
For readers tracking PHVS, this news stream provides insight into the advancement of deucrictibant’s prophylactic and on-demand indications, regulatory filing plans such as the preparation of marketing authorization applications, and the company’s broader efforts in bradykinin-mediated diseases.
Pharvaris has released pharmacological data on its novel bradykinin B2 receptor antagonist, PHA121. This compound demonstrates a 20-fold higher potency than icatibant, the only approved injectable B2 antagonist, while offering improved intrinsic clearance and oral bioavailability. The early clinical data indicates rapid absorption and favorable pharmacokinetics in healthy participants. Pharvaris aims to provide an oral treatment for hereditary angioedema (HAE), showcasing PHA121 as the most potent small-molecule antagonist in its category.
Pharvaris (Nasdaq: PHVS) announced participation in three investor conferences in March 2022. The events include:
- BioCapital Europe 2022 on March 10, 2022, at 3:00 PM CET in Amsterdam.
- Oppenheimer 32nd Annual Healthcare Conference via webcast on March 15, 2022, at 8:00 AM ET.
- SVB Leerink Mountain Meeting on March 22, 2022, at 9:30 AM MT in Jackson Hole, Wyoming.
Pharvaris (Nasdaq: PHVS), a clinical-stage company, announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference, occurring virtually from February 14–18, 2022. The fireside chat is set for February 16 at 4:40 PM CEST (10:40 AM EST). A live audio webcast will be accessible on the Investors section of their website, with a replay available for 30 days post-event. Pharvaris focuses on developing oral bradykinin-B2-receptor antagonists targeting hereditary angioedema and aims to provide alternatives to existing injected therapies.
Pharvaris (Nasdaq: PHVS) announced the appointment of Dr. Anne Marie de Jonge Schuermans to its board of directors, replacing Rémi Droller, effective December 22, 2021. Dr. de Jonge Schuermans, with extensive experience in biotech and pharmaceutical operations, will support Pharvaris as it prepares for commercialization of its oral bradykinin-B2-receptor antagonists aimed at treating hereditary angioedema (HAE). The company anticipates a clinical data readout from Phase 2 trials within the next year, marking a pivotal step in its development strategy.
Pharvaris (Nasdaq: PHVS) has appointed Dr. Elisabeth Björk to its board of directors, effective December 1, 2021, to strengthen its leadership ahead of anticipated Phase 2 clinical data releases for hereditary angioedema (HAE) treatments. Dr. Björk, a seasoned expert in drug development at AstraZeneca, is set to replace Martijn Kleijwegt, who stepped down to focus on new investments. This leadership change aims to enhance Pharvaris’s capabilities as it prepares for commercialization of its bradykinin-B2-receptor antagonists candidates, PHVS416 and PHVS719, in the upcoming years.
Pharvaris (Nasdaq: PHVS) continues its robust clinical development with two Phase 2 studies for PHVS416 aimed at treating hereditary angioedema (HAE). The RAPIDe-1 study for on-demand treatment is progressing, while the CHAPTER-1 study for prophylactic treatment is now recruiting patients. Additionally, a Phase 1 pharmacokinetics study for PHVS719 is set to begin this month. Financially, Pharvaris reported cash and equivalents of €218.6 million as of September 30, 2021, marking a significant increase from €98.6 million at year-end 2020. However, R&D expenses rose to €9.0 million, and the quarterly loss was €9.1 million.
Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on novel oral bradykinin-B2-receptor antagonists, announced its participation in three investor conferences in September 2021. These include the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21. Live audio webcasts will be available on their website, with replays for 30 days following each event.
Pharvaris (Nasdaq: PHVS) reported significant advancements in its clinical programs for PHVS416, a treatment for hereditary angioedema (HAE). The Phase 2 RAPIDe-1 on-demand study is expanding into the US, with data expected in 2022. Additionally, the Phase 2 CHAPTER-1 study for prophylaxis is set to begin in 2021. Financially, the company holds €224.3 million in cash as of June 30, 2021, despite reporting a €15.2 million loss for the quarter. The increase in R&D and G&A expenses highlights the company's growth strategy and investment in clinical studies.
Pharvaris (Nasdaq: PHVS) presented clinical data supporting the safety and pharmacokinetic profile of PHA121 for hereditary angioedema (HAE) at the EAACI Annual Congress 2021. In a double-blind, placebo-controlled study involving 38 healthy volunteers, PHA121 was well-tolerated, with all treatment-emergent adverse events classified as mild. The drug demonstrated dose-proportional absorption with steady-state plasma levels achieved within three days. Pharvaris aims to develop PHA121 into an effective oral treatment for HAE alongside formulations PHVS416 and PHVS719.
Pharvaris (Nasdaq: PHVS) announced the presentation of clinical data for oral PHA121, a bradykinin B2 receptor antagonist for hereditary angioedema (HAE), at the EAACI Annual Congress 2021, from July 10-16. The e-Poster will detail the pharmacokinetic profile and tolerability of PHA121 in multiple dose administration. The abstract will be available on the EAACI website on July 10. Pharvaris focuses on developing oral treatments for HAE, aiming to provide alternatives to injected therapies.